Arguments Against Inhaled Glucocorticoids in COPD by Phenotype Instead of by Severity;Glucocorticoides inhalados en la EPOC por fenotipo en lugar de gravedad. Argumentos en contra

Archivos de Bronconeumologia

Volumn 47, Issue 6, 2011, Pages 269-270

  Rodríguez Roisin, Robert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; HUMAN; PHENOTYPE; COMORBIDITY; DISEASE EXACERBATION; EDUCATIONAL STATUS; FORCED EXPIRATORY VOLUME; MONOTHERAPY; MOTIVATION; PATIENT ATTITUDE; QUALITY OF LIFE; RESPIRATORY FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 85047699935     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.03.001     Document Type: Article

References (16)

1. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
2. Han M.K., Agusti A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
3. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
4. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007, 176:532-555.
5. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term Safety and Efficacy of Indacaterol, a Novel Long-acting [beta]2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011.[ePub ahead of print].
6. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C., et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750.
7. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Update 2010. Disponible en: http://www%20goldcopd%20org/.
8. Jenkins C.R., Jones P.W., Calverley P.M., Celli B., Anderson J.A., Ferguson G.T., et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59.
9. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
10. Agusti A., Calverley P.M., Celli B., Coxson H.O., Edwards L.D., Lomas D.A., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
11. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2010.[ePub ahead of print].
12. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Mullerova H., Tal-Singer R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
13. Garcia-Aymerich J., Barreiro E., Farrero E., Marrades R.M., Morera J., Anto J.M. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000, 16:1037-1042.
14. Soler-Cataluna J.J., Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?. COPD 2010, 7:276-284.
15. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S.R., Fabbri L.M., Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. The Lancet 2009, 374:685-694.
16. Almagro P, Salvadó M., Garcia-Vidal C., Rodriguez-Carballeira M., Delgado M., Barreiro B., et al. Recent improvement in long-term survival after a COPD hospitalisation. Thorax 2010, 65:298-302.